Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma

Methods Adopting multiomics data from TCGA and other public datasets, we analysed the expression, mutation, and prognostic evaluation in multiple cancers. ccRCC patients were categorized into two subgroups by an unsupervised cluster algorithm: melatonin-pattern cancer subtype 1 (MPCS1) and subtype 2 (MPCS2). We then explored the immune microenvironment, immune therapy response, and tumor metabolic pathways between the two subtypes. The clinical characteristics, genomic mutation landscape, and molecular inhibitor response were further investigated. Finally, a melatonin regulator-related prognostic model was constructed to predict patient prognosis in ccRCC. Results We found that melatonin regulators were dysregulated depending on distinct cancer types, which were associated with genomic variation. The two subtypes indicated different clinical characteristics and biological processes in ccRCC. MPCS2, an aggressive subtype, led an advanced clinical stage and poorer survival of ccRCC patients. The activated oncogenic signaling pathway and metabolic signatures were responsible for cancer progression in the MPCS2 subtype. The MPCS2 subgroup suggested a higher tumor mutational burden and immune dysfunction state, resulting in a lower response to immunotherapy. The copy number variations of MPCS2 were significantly more frequent than those of MPCS1. In addition, the two subgroups exhibited distinct drug responsiveness, with MPCS2 being less responsive to multiple drugs. Finally, we established a subtype biomarker-based prognostic risk model that exhibited satisfactory performance in ccRCC patients. Conclusion Melatonin regulator-related features could remodel functional pathways and the tumor immune microenvironment through genomic mutations and pathway regulation. Melatonin regulator-associated molecular subtypes enhance the understanding of the molecular characteristics of renal cancer and can guide clinical treatment. Activating the melatonergic system axis may improve the effect of immunotherapy for ccRCC.

[1]  Q. Tong,et al.  A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma , 2022, Frontiers in Immunology.

[2]  U. Capitanio,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. , 2022, European urology.

[3]  Jialin Meng,et al.  Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma , 2021, Frontiers in Oncology.

[4]  Y. Hsieh,et al.  Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells , 2021, Tzu chi medical journal.

[5]  Peng Zhang,et al.  SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis , 2021, Oncogene.

[6]  R. Reiter,et al.  Pan‐cancer analyses reveal genomics and clinical characteristics of the melatonergic regulators in cancer , 2021, Journal of pineal research.

[7]  Jun‐hang Luo,et al.  N6-Methyladenosine Modification of LncRNA DUXAP9 Promotes Renal Cancer Cells Proliferation and Motility by Activating the PI3K/AKT Signaling Pathway , 2021, Frontiers in Oncology.

[8]  M. Shakibaei,et al.  Metabolic Anti-Cancer Effects of Melatonin: Clinically Relevant Prospects , 2021, Cancers.

[9]  C. Leslie,et al.  Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. , 2021, Cancer cell.

[10]  J. García-Verdugo,et al.  Melatonin Targets Metabolism in Head and Neck Cancer Cells by Regulating Mitochondrial Structure and Function , 2021, Antioxidants.

[11]  Deyong Yang,et al.  Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma , 2021, Frontiers in Immunology.

[12]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[13]  M. Bonmati-Carrion,et al.  Melatonin and Cancer: A Polyhedral Network Where the Source Matters , 2021, Antioxidants.

[14]  Bing Liu,et al.  EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR , 2020, BioMed research international.

[15]  R. Hardeland,et al.  Targeting Host Defense System and Rescuing Compromised Mitochondria to Increase Tolerance against Pathogens by Melatonin May Impact Outcome of Deadly Virus Infection Pertinent to COVID-19 , 2020, Molecules.

[16]  Yujie Zhou,et al.  MOVICS: an R package for multi-omics integration and visualization in cancer subtyping , 2020, bioRxiv.

[17]  J. Duanmu,et al.  Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment , 2020, Journal of Translational Medicine.

[18]  Li Yang,et al.  Melatonin protects mouse testes from palmitic acid‐induced lipotoxicity by attenuating oxidative stress and DNA damage in a SIRT1‐dependent manner , 2020, Journal of pineal research.

[19]  Qinying Huang,et al.  Circadian clock is associated with tumor microenvironment in kidney renal clear cell carcinoma , 2020, Aging.

[20]  S. Saravanan,et al.  Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. , 2020, Life sciences.

[21]  Zhou Zhou,et al.  Melatonin Antagonizes Nickel-Induced Aerobic Glycolysis by Blocking ROS-Mediated HIF-1α/miR210/ISCU Axis Activation , 2020, Oxidative medicine and cellular longevity.

[22]  M. Xiong,et al.  Single-Cell Transcriptome Analysis Reveals Intratumoral Heterogeneity in ccRCC, which Results in Different Clinical Outcomes. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Shengqi Wang,et al.  CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling , 2020, Cell Death & Disease.

[24]  Guang-Yu Bai,et al.  Melatonin protects mouse oocytes from DNA damage by enhancing nonhomologous end‐joining repair , 2019, Journal of pineal research.

[25]  Yuling Chen,et al.  Loss of BAP1 Results in Growth Inhibition and Enhances Mesenchymal–Epithelial Transition in Kidney Tumor Cells* , 2019, Molecular & Cellular Proteomics.

[26]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[27]  F. Speizer,et al.  Rotating night shift work and colorectal cancer risk in the nurses’ health studies , 2018, International journal of cancer.

[28]  Xue Yang,et al.  Inhibition of miR146b‐5p suppresses CT‐guided renal cell carcinoma by targeting TRAF6 , 2018, Journal of cellular biochemistry.

[29]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[30]  Tsui-Chin Huang,et al.  Protective Effect of Melatonin against Oxidative Stress-Induced Apoptosis and Enhanced Autophagy in Human Retinal Pigment Epithelium Cells , 2018, Oxidative medicine and cellular longevity.

[31]  Darren R. Williams,et al.  Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion , 2018, Clinical Cancer Research.

[32]  G. Mayhew,et al.  Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal , 2018, Cell.

[33]  P. A. Futreal,et al.  Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal , 2018, Cell.

[34]  R. Reiter,et al.  Melatonin: A Versatile Protector against Oxidative DNA Damage , 2018, Molecules.

[35]  M. Abdollahi,et al.  Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence , 2017, Toxicology and applied pharmacology.

[36]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[37]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, Genome Biology.

[38]  R. Ordoñez,et al.  Melatonin‐induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy , 2016, Journal of pineal research.

[39]  T. Jacks,et al.  Circadian Rhythm Disruption Promotes Lung Tumorigenesis. , 2016, Cell metabolism.

[40]  Nicolai J. Birkbak,et al.  SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair , 2015, Oncogene.

[41]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[42]  M. Bizzarri,et al.  Melatonin down‐regulates MDM2 gene expression and enhances p53 acetylation in MCF‐7 cells , 2014, Journal of pineal research.

[43]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[44]  A. Hao,et al.  Melatonin antagonizes hypoxia‐mediated glioblastoma cell migration and invasion via inhibition of HIF‐1α , 2013, Journal of pineal research.

[45]  R. Ordoñez,et al.  Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells , 2013, British Journal of Cancer.

[46]  K. Kohn,et al.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.

[47]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[48]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[49]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.

[50]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[51]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[52]  Ralf Herwig,et al.  ConsensusPathDB—a database for integrating human functional interaction networks , 2008, Nucleic Acids Res..

[53]  P. Dasgupta,et al.  Acetylcholinesterase and human cancers. , 2021, Advances in cancer research.

[54]  Yuling Chen,et al.  Loss of BAP1 Results in Growth Inhibition and Enhances Mesenchymal–Epithelial Transition in Kidney Tumor Cells , 2020 .

[55]  L. Stechow.  Cancer Systems Biology , 2018, Methods in Molecular Biology.

[56]  J. Patard,et al.  Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. , 2011, European urology.